Gradient Investments LLC Purchases Shares of 16,437 Halozyme Therapeutics, Inc. $HALO

Gradient Investments LLC acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 16,437 shares of the biopharmaceutical company’s stock, valued at approximately $1,287,000.

Other large investors also recently modified their holdings of the company. Assenagon Asset Management S.A. grew its holdings in Halozyme Therapeutics by 4,578.9% during the second quarter. Assenagon Asset Management S.A. now owns 997,643 shares of the biopharmaceutical company’s stock worth $78,086,000 after buying an additional 976,321 shares in the last quarter. Balefire LLC bought a new position in Halozyme Therapeutics during the 2nd quarter valued at $230,000. GAMMA Investing LLC boosted its holdings in Halozyme Therapeutics by 13.7% during the 2nd quarter. GAMMA Investing LLC now owns 4,487 shares of the biopharmaceutical company’s stock worth $351,000 after acquiring an additional 542 shares during the last quarter. Harbor Investment Advisory LLC bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth $117,000. Finally, Cooper Investors PTY Ltd. bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth $4,307,000. Institutional investors own 97.79% of the company’s stock.

Insiders Place Their Bets

In other news, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director directly owned 14,462 shares of the company’s stock, valued at $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 1,923 shares of Halozyme Therapeutics stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $79.77, for a total value of $153,397.71. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $61,245,810.60. This trade represents a 0.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 72,477 shares of company stock worth $5,102,643 over the last 90 days. Corporate insiders own 2.50% of the company’s stock.

Analysts Set New Price Targets

HALO has been the topic of several recent analyst reports. Morgan Stanley dropped their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. UBS Group restated a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and set a $110.00 price objective for the company in a report on Friday. HC Wainwright lifted their price objective on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $91.20.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $103.12 on Monday. The stock has a market capitalization of $11.70 billion, a P/E ratio of 30.78, a P/E/G ratio of 0.43 and a beta of 0.85. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $103.30. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The stock’s 50-day simple moving average is $76.48 and its 200 day simple moving average is $71.48.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company’s revenue was up 47.7% on a year-over-year basis. During the same quarter last year, the company earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Record Q2 results beat expectations: Halozyme reported adjusted earnings of $2.28 per share, above the roughly $1.79-$1.82 consensus, while revenue rose 48% year over year to $481 million versus estimates near $402 million. Royalty revenue increased 50% to $308 million. Halozyme reports record second quarter 2026 results
• Positive Sentiment: 2026 guidance was raised: Management now expects revenue of $1.835 billion-$1.910 billion, royalty revenue of $1.220 billion-$1.245 billion, adjusted EBITDA of $1.225 billion-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS range is above the approximately $8.02 analyst consensus. Halozyme Q2 earnings beat estimates
• Positive Sentiment: Commercial momentum expanded: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year goal of three. The agreements support the company’s royalty-driven platform model and broaden future revenue opportunities.
• Positive Sentiment: Analyst sentiment improved: Leerink Partners upgraded HALO to “outperform” with a $110 price target. HC Wainwright raised its target to $115 and retained a “buy” rating, while TD Cowen increased its target to $105 and also rated the stock “buy.”
• Neutral Sentiment: Analyst views remain mixed at the elevated valuation: Citizens JMP raised its target to $93 with a “market outperform” rating, and Wells Fargo lifted its target to $95 while maintaining “equal weight.” Both targets remain below the recent trading level, suggesting some analysts see limited near-term upside.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.